首页> 外文期刊>Pediatric blood & cancer >Neuroblastoma progress on many fronts: The neuroblastoma research symposium
【24h】

Neuroblastoma progress on many fronts: The neuroblastoma research symposium

机译:神经母细胞瘤的多方面进展:神经母细胞瘤研究研讨会

获取原文
获取原文并翻译 | 示例
           

摘要

Neuroblastoma (NBL) is a pediatric tumor of infancy derived from precursor cells of the sympathetic nervous system. Clinicians and researchers in developmental biology and genetics recently met to facilitate meaningful crosstalk and to discuss considerable progress made in the clinical treatment and basic biology of NBL. For instance, discoveries in familial NBL have identified genetic aberrations in Phox2b and Alk that predispose to NBL, while advances in epigenetics and MYCN regulation have also offered insight into NBL pathogenesis and future treatment. Moreover, novel therapeutic avenues are also being explored, including targeted immunotherapies, and innovative radiotherapeutic and chemotherapeutic approaches. This multi-disciplinary meeting was convened to aid the transfer of new biological findings into the clinic and to use clinical advances to inform the basic biological understanding of this devastating disease.
机译:神经母细胞瘤(NBL)是由交感神经系统前体细胞衍生的婴儿期儿科肿瘤。发育生物学和遗传学的临床医生和研究人员最近举行会议,以促进有意义的相声交流,并讨论了NBL的临床治疗和基础生物学取得的重大进展。例如,家族性NBL的发现已经确定了Phox2b和Alk中的遗传异常,这是NBL的诱因,而表观遗传学和MYCN调控的进步也为NBL的发病机理和未来治疗提供了见识。此外,还正在探索新颖的治疗途径,包括靶向免疫治疗以及创新的放射治疗和化学治疗方法。召开这次多学科会议是为了帮助将新的生物学发现转移到临床中,并利用临床进展为这种破坏性疾病提供基本的生物学知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号